ArticleJournal of translational medicine2025
Strategic trimodal therapy enhances radiation-induced abscopal response in renal cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway.Clinical and experimental medicine · 2026Article
- RGS19 drives tumor progression and immunosuppression in clear cell renal cell carcinoma by modulating CAMs and EMT.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe abscopal effect, tumor regression at distant, non-irradiated sites following localized radiotherapy, is rarely observed, even in immunogenic cancers such as renal cell carcinoma. Current strategies have largely failed to reliably enhance this phenomenon. This study aimed to develop and evaluate a novel therapeutic approach to potentiate the abscopal effect using a combination of tumor-targeted liposomal everolimus and YM155 (EY-L), radiation, and interleukin-2 (IL-2).
methodsA trimodal therapy comprising EY-L, localized radiation, and systemic IL-2 was tested in two murine renal cancer models (Renca and LVRCC67) using a bilateral tumor setup to distinguish local and distant tumor responses. The efficacy of the triple therapy was compared to that of single and dual combinations. Downstream analyses including immunohistochemistry, CD8
resultsIn the Renca model, the EY-L + R + IL-2 triple combination significantly suppressed growth in both irradiated and non-irradiated tumors, demonstrating a robust enhancement of the abscopal effect. Dual combinations failed to elicit similar systemic responses, underscoring the necessity of the full triple regimen. Mechanistic analyses revealed increased infiltration of CD8⁺ T cells and reduced CD163
conclusionThis study presents a novel and effective strategy to induce the abscopal effect through a synergistic combination of targeted drug delivery, radiotherapy, and immunotherapy. The approach offers strong translational potential for improving radioimmunotherapy outcomes in renal and potentially other immunogenic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.